Parexel turns Q4 profit on 26% revenue boost

Parexel International ($PRXL) raked in a $17.8 million net profit in its fiscal fourth quarter, which ended June 30, a big turnaround from the $1.6 million loss the company took in the period last year. Parexel credits a 26.4% spike in revenue, bringing in $392.6 million for the quarter, due in part to the company's decrease in year-to-year restructuring charges. The company saw its largest revenue growth in clinical research, which pulled in $292 million in the quarter. Release

Suggested Articles

The money will be used to expand its footprint in both China and the U.S., including a new R&D operation in Boston.

Aetion has raised $50 million so far, and it plans to enhance its platform to support more complex therapeutic areas and expand its team.

Charles River partners with PathoQuest to offer clients NGS solutions for biologics viral contamination testing and cell-line genetic characterization.